BioCentury
ARTICLE | Financial News

Actelion gains on Opsumit approval

October 21, 2013 11:39 PM UTC

Actelion Ltd. (SIX:ATLN) gained CHF3.80 (5.9%) to CHF68.40 on Monday after FDA approved the company's Opsumit macitentan for pulmonary arterial hypertension (PAH) late Friday. The biotech said it has ...